NanoViricides, Inc. (NNVC) Sees Significant Decrease in Short Interest

NanoViricides, Inc. (NYSEAMERICAN:NNVC) was the target of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 1,431,399 shares, a decrease of 3.1% from the October 31st total of 1,476,924 shares. Currently, 3.0% of the company’s shares are sold short. Based on an average trading volume of 80,071 shares, the short-interest ratio is currently 17.9 days.

Separately, BidaskClub cut NanoViricides from a “sell” rating to a “strong sell” rating in a report on Saturday, November 4th.

Shares of NanoViricides (NYSEAMERICAN NNVC) opened at $1.04 on Friday. NanoViricides has a twelve month low of $0.91 and a twelve month high of $1.64.

NanoViricides (NYSEAMERICAN:NNVC) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.03) earnings per share (EPS) for the quarter.

WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/02/nanoviricides-inc-nnvc-sees-significant-decrease-in-short-interest.html.

About NanoViricides

NanoViricides, Inc is a nano-biopharmaceutical company. The Company is a development-stage company with several drugs in various stages of development. The Company focuses on its research and clinical programs on specific anti-viral therapeutics. The Company is engaged in the application of nanomedicine technologies to the issues of viral diseases.

What are top analysts saying about NanoViricides Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NanoViricides Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit